» Articles » PMID: 34106777

Gender-specific Cut-off Levels in Colorectal Cancer Screening with Fecal Immunochemical Test: A Population-based Study of Colonoscopy Findings and Costs

Overview
Journal J Med Screen
Specialty Public Health
Date 2021 Jun 9
PMID 34106777
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: In the population-based Swedish regional colorectal cancer (CRC) screening program of Stockholm-Gotland using the fecal immunochemical test (FIT), gender-specific cut-off levels of fecal hemoglobin are applied, since previous studies have indicated a lower sensitivity of FIT for CRC in women. The aim was to evaluate the diagnostic yield and the screening costs overall and per detected CRC of this strategy.

Methods: All individuals aged 60-69 invited to screening in 2015-2017 were included. Cut-off level for positive FIT was 40 µg/g in women and 80 µg/g in men. Those with a positive FIT were referred to colonoscopy. The yield of CRC and screening cost for the study period were assessed and compared to cut-off levels of 80 µg/g in both genders.

Results: Approximately 230,000 individuals were invited. Overall participation rates were 72% in women and 65% in men ( < 0.05). FIT was positive in 4256 individuals (2.7% in both genders). In 3758 colonoscopies, 258 (6.9%) CRCs were detected. The positive predictive value for CRC was significantly higher in men (8.3% vs. 5.8%). In 120 women with CRC, 28 (23%) had FIT < 80 µg/g. Negative colonoscopies were more common in women (24% vs. 17%, 0.05). Total costs for the study period were 52,000,000SEK (≈5,200,000€), i.e. 16% higher compared to using cut-off levels of 80 µg/g in both genders, and corresponding to a 3% increment in cost per detected CRC.

Conclusion: The high rate of CRC detected in women in the lowest FIT category outweighs the minor reduction in screening costs if the same cut-off level was used as for men.

Citing Articles

Levelling up as a fair solution in AI enabled cancer screening.

Abdulrahman S, Trengove M Front Digit Health. 2025; 7:1540982.

PMID: 40070542 PMC: 11893865. DOI: 10.3389/fdgth.2025.1540982.


Costs of colorectal cancer screening in Sweden: an observational, longitudinal cost description.

Johansson N, Nystrand C, Blom J BMJ Open Gastroenterol. 2024; 11(1.

PMID: 39694626 PMC: 11667418. DOI: 10.1136/bmjgast-2024-001574.


Serum Interleukins 8, 17, and 33 as Potential Biomarkers of Colon Cancer.

Talvan C, Budisan L, Talvan E, Grecu V, Zanoaga O, Mihalache C Cancers (Basel). 2024; 16(4).

PMID: 38398137 PMC: 10886755. DOI: 10.3390/cancers16040745.


Interval colorectal cancers after negative faecal immunochemical test in the New Zealand Bowel Screening Pilot.

Saw K, Sexton K, Frankish P, Hulme-Moir M, Bissett I, Parry S BMJ Open Gastroenterol. 2023; 10(1).

PMID: 38007223 PMC: 10679982. DOI: 10.1136/bmjgast-2023-001233.


A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities?.

Pokharel R, Lin Y, McFerran E, OMahony J Appl Health Econ Health Policy. 2023; 21(5):701-717.

PMID: 37380865 PMC: 10403417. DOI: 10.1007/s40258-023-00819-3.